BCL-2-inhibitor

BCL-2 inhibitor (BH3 mimetic)

一行要約

BCL-2 ファミリー抗アポトーシスタンパク質 (BCL-2 / BCL-XL / MCL-1) の BH3-binding groove を模倣阻害する small molecule 群。Venetoclax (ABT-199、BCL-2 selective) は CLL / AML で class-defining 承認を確立し、navitoclax (ABT-263、BCL-2/BCL-XL/BCL-w pan-inhibitor) は BCL-XL 依存の血小板減少が dose-limiting。SCLC では ASCL1-driven transcription program が BCL-2 を高発現させ (SCLC-A subtype の 約80%)、BH3 profiling で apoptosis priming の高い subset が venetoclax 感受性を示す preclinical rationale が確立されている (Gay et al. CancerCell 2021)。肺癌領域では (1) SCLC subtype-guided venetoclax + chemo 併用、(2) EGFR-TKI 耐性の drug-tolerant persister (DTP) state に対する senolytic navitoclax 併用、(3) NE-differentiation と BCL-2 依存の連動を利用した Lineage-plasticity 耐性への対抗 が 3 大 translational axis として探索される。

メンバー比較表

薬剤	開発コード	標的選択性	承認適応	Ki / IC50	SCLC / NSCLC 状況	主要 DLT
Venetoclax	ABT-199	BCL-2 selective (Ki < 0.01 nM)	CLL (+Rituximab) / AML (+Azacitidine / cytarabine)	BCL-2: <0.01 nM; BCL-XL: 48 nM	SCLC phase I/II (BCL-2high subset) ; NSCLC 単剤 inactive	Neutropenia, TLS (tumor lysis syndrome)
Navitoclax	ABT-263	BCL-2 / BCL-XL / BCL-w pan-inhibitor	未承認 (myelofibrosis phase III 進行中)	BCL-2: <1 nM; BCL-XL: <1 nM	SCLC phase I/II; senolytic 併用探索	血小板減少 (BCL-XL が巨核球/血小板生存に必須)
ABT-737	—	BCL-2 / BCL-XL / BCL-w (navitoclax 前駆体)	Preclinical tool	BCL-2: 1 nM	BH3 mimetic concept proof (Oltersdorf Nature 2005)	経口 bioavailability なし
S63845 / S64315 (MIK665)	—	MCL-1 selective	Phase I (hematologic)	MCL-1: <1 nM	SCLC MCL-1 依存 subset; cardiac safety 懸念	Cardiac toxicity (cardiomyocyte MCL-1 依存)
AZD5991	—	MCL-1 selective	Phase I	MCL-1: <1 nM	Venetoclax + MCL-1i 併用 rationale	Cardiac toxicity
Pelcitoclax (APG-1252)	—	BCL-2 / BCL-XL dual	Phase I (SCLC cohort)	BCL-2/BCL-XL dual	SCLC phase I data	血小板減少

主要エビデンス

CLL / AML — class validation

Venetoclax + Rituximab (CLL)

Roberts et al. NEJM 2016 は CLL に venetoclax 単剤 phase I (escalation 20-1200 mg) を報告: ORR 79%、CR 20%。TLS management が critical (dose ramp-up protocol 確立)。続く MURANO trial (venetoclax + rituximab vs BR) で PFS HR 0.17 → CLL 2L standard 確立。Fixed-duration therapy (2 年) で MRD-undetectable を達成 → 治療中止可能な paradigm。

Venetoclax + Azacitidine (AML)

DiNardo et al. NEJM 2020 は untreated AML elderly (intensive chemo unfit) に venetoclax + azacitidine: CR+CRi 66.4%、mOS 14.7 mo vs azacitidine alone 9.6 mo → AML unfit 患者の standard-of-care 変革。IDH1/2 mutation / NPM1 mutation 陽性例で特に高感度 (CR率 約80%) → molecular biomarker-guided use の model。

BH3 mimetic concept の確立

Oltersdorf et al. Nature 2005 は ABT-737 (navitoclax 前駆体) を合成し、BCL-2/BCL-XL/BCL-w の BH3-binding groove に direct binding して BAX/BAK を liberation する BH3 mimetic concept を実証した landmark paper。Structural biology (NMR-based fragment screen → SAR optimization) による rational drug design の成功例。FL / CLL xenograft で single-agent activity を示し、BH3 mimetic class の foundation を築いた。

SCLC — BCL-2 dependency と clinical translation

ASCL1 → BCL-2 transcriptional axis

Rudin et al. NatRevCancer 2019 / Gay et al. CancerCell 2021 が整理した SCLC molecular subtypes において:

• SCLC-A (ASCL1-high) : ASCL1 が BCL-2 promoter を直接 transactivate → BCL-2 protein 高発現 (IHC 約80% positive)。BH3 profiling で “primed for death” 状態 → venetoclax 高感受性の予測
• SCLC-N (NEUROD1-high) : BCL-2 中等度発現。MCL-1 への dependency shift が一部
• SCLC-P (POU2F3-high) : BCL-2 依存が heterogeneous。Tuft cell-like differentiation program
• SCLC-I (Inflamed) : BCL-2 低発現が多い。IO 候補 subtype

この subtype-BCL-2 dependency mapping は venetoclax の biomarker-selected trial の rational base を提供する。

Lochmann et al. Cancer Discov 2018 — dependency mapping

Lochmann 2018 は SCLC cell line panel + PDX で BCL-2 / MCL-1 / BCL-XL dependency を BH3 profiling + CRISPR screen で系統的に mapping:

• BCL-2-dependent lines (約40%) は venetoclax 単剤に high sensitivity (IC50 < 100 nM)
• MCL-1-dependent lines (約30%) は venetoclax 耐性だが S63845 (MCL-1i) 感受性
• BCL-2 + MCL-1 co-dependent lines は dual inhibition で synthetic lethality
• Chemo (etoposide) は BIM upregulation を介して BCL-2 dependency を増大 → chemo → venetoclax sequential strategy の rationale

SCLC clinical data

• Venetoclax + platinum/etoposide phase I/Ib: Tolerability 確認。BCL-2 IHC high subset で PR 観察
• Navitoclax + etoposide phase I: 血小板減少が dose-limiting だが、BCL-XL 依存 subset で activity signal
• Liu et al. Cell 2024 は SCLC proteogenomics で subtype-specific therapeutic vulnerabilities を定量化し、BCL-2 targeting の precision medicine 基盤を提供

BH3 profiling — functional apoptosis biomarker

BH3 profiling は mitochondrial “priming for death” を functional assay で測定する手法: BH3-only peptide (BIM BH3 / BAD BH3 / HRK BH3 等) を permeabilized cell に添加し、cytochrome c release を定量。

• Overall priming (BIM BH3 response) : apoptosis への proximity → chemo sensitivity predictor
• BCL-2 dependency (ABT-737 sensitivity in assay) : venetoclax response predictor
• MCL-1 dependency (MS1 peptide response) : MCL-1i response predictor

Davids 2012 JCO は CLL で BH3 profiling が venetoclax response を prospectively 予測することを示した。SCLC への translational application として、biopsy sample での BH3 profiling → venetoclax patient selection が探索中。

Senolytic 応用 (Navitoclax)

Cancer therapy-induced senescence と senolytic 戦略

化学療法 / 放射線 / CDK4/6 inhibitor は腫瘍細胞の一部に therapy-induced senescence (TIS) を誘導する。Senescent cell は cell cycle arrest するが、SASP (senescence-associated secretory phenotype: IL-6 / IL-8 / MMP / VEGF / TGF-β) を分泌し、TME のリモデリング・免疫抑制・隣接非 senescent cell の増殖促進を行う。

Navitoclax は senescent cell が BCL-XL dependent であることを利用した senolytic agent:

• Senescent cell は DNA damage response → p53/p21 activation → cell cycle arrest だが、apoptosis は BCL-XL upregulation で回避
• Navitoclax (BCL-XL inhibitor) は senescent cell を選択的に apoptosis 誘導 (senolysis)
• Hinterleitner et al. Cell 2026 は senescence の cancer における hallmarks と therapeutic promise を体系化

Shahbandi et al. Cancer Discov 2022 は chemo-induced senescent tumor cell で navitoclax がsenolysis を実現し、残存腫瘍の re-growth を抑制することを in vivo で示した。

Senolytic + IO combination

Senolysis → SASP 除去 → TME の immunosuppression 解除 → T cell infiltration 促進 → ICI efficacy 増強。Chemo → navitoclax (senolysis) → anti-PD-1 の sequential “one-two-three punch” 戦略が preclinical で有望。

NSCLC における BCL-2i の位置づけ

EGFR-TKI resistance と DTP state

Hata et al. NatMed 2016 は EGFR-TKI 耐性が (1) pre-existing resistant clone selection と (2) drug-tolerant persister (DTP) からの de novo mutation acquisition の 2 経路で進行することを実証。DTP state は epigenetically reprogrammed で、BCL-XL / MCL-1 upregulation により apoptosis を escape している → BH3 mimetic (navitoclax / MCL-1i) による DTP state 狙い打ち が耐性予防戦略として提唱される。

NE transformation と BCL-2

Niederst et al. NatCommun 2015 は EGFR-TKI 耐性の SCLC transformation (NE lineage switch) で RB1 loss + BCL-2 upregulation が共起することを示した。NE-transformed tumor は original adenocarcinoma と異なる therapeutic vulnerability を獲得 → venetoclax + platinum/etoposide が NE-transformed 耐性腫瘍の treatment option として探索される。

メカニズム

BCL-2 ファミリーの分子構造と相互作用

BCL-2 ファミリーは mitochondrial outer membrane permeabilization (MOMP) の master regulator:

Anti-apoptotic (pro-survival) members:

• BCL-2: CLL / AML / SCLC-A で high expression。Outer mitochondrial membrane + ER に局在
• BCL-XL: 血小板 / cardiomyocyte 生存に必須。固形腫瘍で broad upregulation
• MCL-1: 半減期が短い (約30 min) → transcriptional / post-translational regulation に sensitive。多くの固形腫瘍の survival signal
• BCL-w / BFL-1 / A1: tissue-restricted expression

Pro-apoptotic effectors:

• BAX / BAK: MOMP の direct executioner。Oligomerization → mitochondrial outer membrane pore → cytochrome c release

BH3-only proteins (sentinels) :

• Activators: BIM / BID / PUMA → 直接 BAX/BAK を activate
• Sensitizers: BAD / NOXA / HRK / BMF → anti-apoptotic members に結合して BIM/BID を liberation

BH3 mimetic の作用機序

1. BH3 mimetic (venetoclax / navitoclax) が anti-apoptotic protein (BCL-2 / BCL-XL) の BH3-binding hydrophobic groove に competitive に結合
2. 結合していた BH3-only protein (BIM / BID) が release
3. Free BIM/BID が BAX/BAK を direct activation
4. BAX/BAK が oligomerize → mitochondrial outer membrane に pore 形成
5. Cytochrome c が cytoplasm に release → Apaf-1 / caspase-9 apoptosome 形成 → caspase-3/7 活性化 → apoptosis execution

Synthetic lethality model (DNA damage + BH3 mimetic)

Platinum / etoposide 等の DNA damaging agent は:

1. DNA double-strand break → ATM/ATR → p53 activation → PUMA / NOXA transcription upregulation
2. E2F1 de-repression → BIM transcription
3. BIM / PUMA / NOXA が BCL-2 に binding → BCL-2 の “buffering capacity” を消費
4. BCL-2 が saturated → BH3 mimetic addition で残る buffering を一気に破壊 → MOMP → apoptosis

この 2-hit model が chemo + venetoclax sequential strategy の分子基盤。

選択性の臨床的意義

特性	Venetoclax (BCL-2 selective)	Navitoclax (BCL-2/BCL-XL pan)
血小板	温存 (血小板は BCL-XL 依存)	減少 (grade 3/4 約30%)
抗腫瘍 spectrum	BCL-2 dependent tumor に限定	より広い (BCL-XL dependent 固形腫瘍にも)
Senolytic 活性	弱い (senescent cell は BCL-XL 依存)	強い
心毒性	低い	低い (cardiomyocyte は MCL-1 依存)
TLS risk	高い (CLL で顕著 → dose ramp-up 必須)	中等

耐性メカニズム

1. MCL-1 upregulation: BCL-2 inhibition → compensatory MCL-1 upregulation (transcriptional / post-translational stabilization) → BAX/BAK を MCL-1 が sequester → venetoclax 耐性。MCL-1 + BCL-2 dual inhibition が rational だが cardiac toxicity が barrier
2. BCL-XL switch: CLL で BCL-2 → BCL-XL dependency shift → venetoclax 耐性
3. BAX/BAK LOF mutation: Rare だが CRISPR screen で同定。BAX/BAK loss → complete MOMP block
4. TP53 mutation: p53 LOF → BIM / PUMA induction 障害 → DNA damage-mediated priming 低下 → synthetic lethality 消失
5. Metabolic rewiring: OXPHOS shift → mitochondrial fitness 改善 → apoptosis threshold 上昇
6. Epigenetic silencing of BH3-only genes: BIM promoter methylation → apoptotic signal loss

Conrad et al. Cell 2026 — cell death in cancer の統合フレームワーク

Conrad et al. Cell 2026 は apoptosis (intrinsic / extrinsic) に加え、necroptosis / ferroptosis / pyroptosis / cuproptosis 等の regulated cell death (RCD) を cancer therapy の文脈で統合的に review。BCL-2 inhibitor は intrinsic apoptosis pathway の selective activator として位置づけられ、他の RCD modality との combinatorial exploitation が next frontier として提唱される。

臨床位置づけ

承認済み (血液腫瘍)

• CLL: Venetoclax + rituximab (2L standard) / venetoclax + obinutuzumab (1L unfit)
• AML: Venetoclax + azacitidine / low-dose cytarabine (unfit elderly 1L standard)

SCLC での探索的位置づけ

• Patient selection: BCL-2 IHC high (H-score >200) + ASCL1 subtype → venetoclax 最感受性 population
• Combination partner: Platinum/etoposide (DNA damage-mediated priming) / AURK inhibitor (SCLC-A/N crossover)
• Sequencing: 1L chemo + maintenance venetoclax / 2L venetoclax + lurbinectedin の探索
• Biomarker: BH3 profiling (functional) > BCL-2 IHC (expression) > ASCL1 subtype (surrogate) の hierarchy

NSCLC での potential niche

• NE-transformed EGFR-TKI 耐性: RB1 loss + BCL-2 up → venetoclax + platinum/etoposide
• DTP targeting: Navitoclax as senolytic → TKI + navitoclax sequential to prevent DTP outgrowth
• Senolytic + IO: Chemo → senescence → navitoclax senolysis → anti-PD-1

開発中の次世代 BH3 mimetic

• MCL-1 selective inhibitor (S64315 / AZD5991 / AMG 176) : Cardiac safety が最大課題。Venetoclax + MCL-1i dual → CLL / AML で phase I 進行
• BCL-XL selective with platelet-sparing (DT2216 等の BCL-XL PROTAC) : degrader 技術で BCL-XL を nucleated cell のみで分解 → 血小板温存戦略
• Dual BCL-2/BCL-XL inhibitor (pelcitoclax / APG-1252) : SCLC で phase I cohort 進行中

Open Questions

• SCLC subtype-guided BCL-2i trial: SCLC molecular subtypes の ASCL1-high subtype で BCL-2 IHC / BH3 profiling による patient selection → venetoclax + chemo の prospective biomarker-driven trial の design と実現性
• MCL-1 inhibitor の cardiac safety 解決: MCL-1 が cardiomyocyte survival に必須 → 心筋温存 strategy (cardiac-sparing delivery / pulsed dosing / degrader approach)
• Venetoclax + MCL-1i dual inhibition の therapeutic window: CLL/AML での dose-finding → SCLC への expansion path
• Senolytic sequential strategy の prospective validation: Chemo → senescence induction → navitoclax senolysis → IO の sequential timing optimization
• DTP state targeting: EGFR-TKI / ALK-TKI 初期治療中の BH3 mimetic 併用で DTP 出現を prevent → resistance delay の preclinical → clinical translation
• BCL-XL PROTAC (DT2216 等) の clinical development: Platelet-sparing BCL-XL degradation → navitoclax の DLT を bypass して BCL-XL dependent tumor に到達
• NE lineage plasticity と BCL-2 dependency の dynamics: EGFR-mut adenocarcinoma → SCLC transformation 時に BCL-2 dependency が emerge → transformation 後の venetoclax window
• Biomarker hierarchy の standardization: BH3 profiling (functional, complex) vs BCL-2 IHC (simple, accessible) vs ASCL1/NEUROD1 transcription factor subtyping の practical clinical workflow
• Combination with IO: Venetoclax-mediated apoptosis → immunogenic cell death → antigen release → IO response enhancement の possibility

重要論文 Top 10

1. Oltersdorf et al. — ABT-737 — BH3 mimetic concept proof、class の foundation
2. Roberts et al. — Venetoclax CLL phase I — class pivotal、dose ramp-up 確立
3. DiNardo et al. — Venetoclax + azacitidine AML — unfit elderly SOC 変革
4. Lochmann et al. — SCLC BCL-2/MCL-1 dependency mapping — 肺癌 translation 基盤
5. Gay et al. CancerCell 2021 — SCLC 4 subtype vulnerability — BCL-2 依存の subtype 文脈

関連エンティティ・概念

• 関連 class: Platinum-chemotherapy (synthetic lethality partner — DNA damage → BH3-only upregulation), PD-1-inhibitor (senolytic + IO sequential), CDK4-6-inhibitor (senescence inducer → BH3 mimetic senolysis target), AURK-inhibitor (SCLC combination partner)
• 概念: SCLC molecular subtypes (ASCL1 subtype-dependent BCL-2 sensitivity), Lineage-plasticity (NE→non-NE shift と BCL-2 / MCL-1 dependency dynamics), Drug-tolerant-persister (DTP state の BCL-XL 依存と senolytic targeting), Synthetic-lethality (DNA damage + apoptosis block 解除)
• 遺伝子/パスウェイ: BCL-2 / BCL-XL / MCL-1 / BAX / BAK / BIM / PUMA / NOXA / TP53 / ASCL1 / NEUROD1
• ドメイン: lung-cancer-treatment, lung-cancer-biology, cancer-biology

関連論文

直近 30 件のみ表示中 (関連 32 件)。 全件は MOC ページ または Obsidian (source Markdown) から辿れます。

Basic-Extracellular vesicles

• Swanton et al. Cell 2024 — Embracing cancer complexity Hallmarks of systemic disease

Basic-Immunotherapy

• Galassi et al. CancerCell 2024 — The hallmarks of cancer immune evasion

Basic-Liquid-biopsy

• Hartono et al. NatAging 2026 — Urinary detection of therapy-induced senescence and fibrosis using an injectable albumin-based nanoprobe

Basic-Neutrophil and myeloid cell

• Haston et al. CancerCell 2023 — Clearance of senescent macrophages ameliorates tumorigenesis in KRAS-driven lung cancer
• He et al. CancerCell 2025 — Chemotherapy awakens dormant cancer cells in lung by inducing neutrophil extracellular traps
• Salladay-Perez et al. NatAging 2026 — P21+trem2+ senescent macrophages fuel inflammaging and metabolic dysfunction-associated steatotic liver disease
• Rys et al. TrendsCellBiol 2025 — Senescent neutrophils a hidden role in cancer progression

Basic-Oncogene and genetics

• Hanahan et al. Cell 2011 — Hallmarks of cancer the next generation
• Hahn et al. Cell 2021 — An expanded universe of cancer targets
• Hoelder et al. MolOncol 2012 — Discovery of small molecule cancer drugs successes, challenges and opportunities
• Friedman et al. NatRevCancer 2015 — Precision medicine for cancer with next-generation functional diagnostics
• Rotow et al. NatRevCancer 2017 — Understanding and targeting resistance mechanisms in NSCLC
• Dagogo-Jack et al. NatRevClinOncol 2018 — Tumour heterogeneity and resistance to cancer therapies
• Bonnal et al. NatRevClinOncol 2020 — Roles and mechanisms of alternative splicing in cancer-implications for care

Basic-Others

• Garciaz et al. CancerDiscov 2022 — Pharmacologic reduction of mitochondrial iron triggers a noncanonical BAXBAK-dependent cell death
• Marinello et al. CancerDiscov 2026 — Approaches in non-small cell lung cancer 2
• Conrad et al. Cell 2026 — Cell death in cancer
• Hinterleitner et al. Cell 2026 — Senescence in cancer hallmarks, paradoxes, and therapeutic promise
• Yue et al. Nature 2026 — Spatial distribution of the proteome in the human body and in cancers

Clinical-NEC

• Lantuejoul et al. TranslLungCancerRes 2020 — New molecular classification of large cell neuroendocrine carcinoma and small cell lung carcinoma with potential

Clinical-NSCLC-ALK

• Tanimoto et al. ClinCancerRes 2021 — Proteasome inhibition overcomes ALK-TKI resistance in ALK-RearrangedTP53-mutant NSCLC via noxa expression

Clinical-NSCLC-Driver-Other

• Vasan et al. ClinCancerRes 2014 — A RAS renaissance emerging targeted therapies for KRAS-mutated non-small cell lung cancer

Clinical-NSCLC-EGFR

• Shi et al. ClinCancerRes 2017 — Overcoming acquired resistance to AZD9291, A third-generation EGFR inhibitor, through modulation of MEKERK-dependent
• Rosell et al. Lancet 2013 — Genetics and biomarkers in personalisation of lung cancer treatment
• Watanabe et al. MolCancerTher 2017 — T790M-selective EGFR-TKI combined with dasatinib as an optimal strategy for overcoming EGFR-TKI resistance in
• Niederst et al. NatCommun 2015 — RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer
• Hata et al. NatMed 2016 — Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition

Clinical-SCLC

• Frese et al. CancerCell 2021 — Small cell lung cancer enters the era of precision medicine
• Rudin et al. NatRevCancer 2019 — Molecular subtypes of small cell lung cancer a synthesis of human and mouse model data
• Pillai et al. SeminOncol 2014 — Small cell lung cancer therapies and targets